Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

• Status: Terminated
• Trial end date: 2018-11-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in adult participants with induced viral upper respiratory tract infections (URTI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• In good general health

• Susceptible to human rhinovirus type 16 (HRV-16)

• Male or non-pregnant and non-breast feeding female

• If female of reproductive potential, agrees to use 1 form of acceptable birth control

Exclusion Criteria:

• Donated blood within 56 days or donated plasma within 7 days prior to dosing

• History of significant multiple and/or severe allergies

• Recent history of respiratory tract infection

• History of cancer

• Body mass index <18 kg/m^2 or ≥40 kg/m^2

• History of major surgery or loss of 1 unit of blood

• History of allergic reaction to sulfonamides

• Received medications within 14 days prior to randomization

• Significantly abnormal laboratory tests at Screening

• Current smoker, smoked within 5 years of Screening, or significant past smoking history

• History of alcohol or drug abuse